Lumos Pharma Inc. (LUMO)
NASDAQ: LUMO
· Real-Time Price · USD
4.34
0.00 (0.00%)
At close: Dec 11, 2024, 10:00 PM
Lumos Pharma Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 2.21M | 1.49M | 1.52M | 2.05M | 1.74M | 2.23M | 2.1M | 1.52M | 1.23M | 734K | 341K | 230K | 50K | 124K | 147K |
Cost of Revenue | 22K | 30K | 37K | 44K | 61K | 53K | 44K | 47K | 12K | 22K | 22K | 180K | 180K | 170K | 170K |
Gross Profit | 2.18M | 1.46M | 1.49M | 2.01M | 1.68M | 2.17M | 2.06M | 1.48M | 1.22M | 712K | 319K | 50K | -130K | -46K | -23K |
Operating Income | -36.33M | -37.62M | -39.44M | -36.61M | -35.45M | -34.06M | -32.34M | -32.04M | -29.77M | -29.72M | -30.46M | -31.35M | -31.83M | -31.49M | -29.7M |
Interest Income | 689K | 967K | 1.46M | 1.87M | 2.08M | 1.92M | 1.44M | 874K | 376K | 86K | 14K | 12K | 9K | 175K | 247K |
Pretax Income | -34.92M | -35.75M | -37.16M | -34.06M | -32.87M | -31.82M | -30.7M | -31.07M | -29.09M | -29.33M | -30.16M | -31.07M | -31.86M | -25.04M | -23.14M |
Net Income | -34.92M | -35.75M | -37.13M | -33.34M | -31.56M | -30.51M | -29.34M | -30.4M | -28.36M | -28.6M | -29.51M | -30.43M | -27.2M | -17.95M | -14.63M |
Selling & General & Admin | 15.82M | 15.51M | 15.97M | 16.55M | 16.88M | 16.91M | 16.44M | 15.71M | 14.65M | 14.12M | 14.99M | 15.33M | 16.53M | 18.3M | 17.89M |
Research & Development | 22.69M | 23.58M | 24.98M | 22.1M | 20.3M | 19.38M | 18M | 17.86M | 16.36M | 16.34M | 15.81M | 16.25M | 15.35M | 13.31M | 11.96M |
Other Expenses | n/a | n/a | n/a | n/a | 72K | 79K | 85K | 91K | 19K | 19K | 5K | 19K | 4K | -3K | 29K |
Operating Expenses | 38.51M | 39.09M | 40.95M | 38.65M | 37.18M | 36.29M | 34.45M | 33.56M | 31M | 30.45M | 30.8M | 31.58M | 31.88M | 31.62M | 29.85M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | 74K | 74K | 74K | 74K | n/a | 37K | 37K | 37K | 37K |
Selling & Marketing Expenses | -22K | -22K | -20K | -18K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 38.53M | 39.11M | 40.97M | 38.66M | 37.18M | 36.29M | 34.45M | 33.56M | 31M | 30.45M | 30.8M | 31.58M | 31.88M | 31.62M | 29.85M |
Income Tax Expense | -41.28K | -49.28K | -78.28K | -726K | -1.31M | -1.31M | -1.36M | -679K | -727K | -720K | -648K | -580K | -4.6M | -7.04M | -8.45M |
Shares Outstanding (Basic) | 8.33M | 8.11M | 8.1M | 8.1M | 7.98M | 8.16M | 8.24M | 8.27M | 8.39M | 8.36M | 8.36M | 8.34M | 8.32M | 8.73M | 8.32M |
Shares Outstanding (Diluted) | 8.33M | 8.11M | 8.1M | 8.1M | 7.98M | 8.16M | 8.24M | 8.27M | 8.39M | 8.37M | 8.36M | 8.36M | 8.36M | 8.73M | 8.32M |
EPS (Basic) | -4.29 | -4.43 | -4.59 | -4.11 | -3.87 | -3.69 | -3.53 | -3.64 | -3.39 | -3.43 | -3.49 | -3.61 | -3.22 | -2.11 | -1.77 |
EPS (Diluted) | -4.29 | -4.43 | -4.59 | -4.11 | -3.87 | -3.69 | -3.53 | -3.64 | -3.38 | -3.42 | -3.48 | -3.6 | -3.22 | -2.11 | -1.77 |
EBITDA | -36.31M | -37.59M | -39.4M | -36.57M | -35.38M | -34.01M | -32.22M | -31.91M | -29.87M | -29.8M | -30.61M | -31.32M | -31.41M | -24.54M | -22.42M |
EBIT | -36.33M | -37.62M | -39.44M | -36.61M | -35.84M | -34.45M | -32.65M | -32.35M | -29.72M | -29.66M | -30.48M | -31.35M | -38.53M | -31.71M | -29.82M |
Depreciation & Amortization | 22K | 30K | 37K | 44K | 61K | 57K | 46K | 49K | 24K | 30K | 115K | 273K | 472K | 617K | 745K |